Despite the availability of both effective preventive vaccines and oral antivirals, over 250
million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic …

Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to
support enhanced prevention, diagnosis and treatment. On the basis of insights from …

To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …

Background & Aims The comparative risk of hepatocellular carcinoma (HCC) in patients with
chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) …

A substantial proportion of patients with chronic hepatitis B (CHB) who do not fit into any of
the usual immune states are considered to be in the 'grey zone (GZ)'. We aimed to …

Sexual dimorphism in infectious diseases refers to the different infection susceptibilities and
outcomes between males and females, and has been described for many pathogens …

Chronic hepatitis B (CHB) remains a global healthcare burden. Although the recent
developments in the field have led to a reduction in incidence, the morbidity and mortality …

The current treatment of chronic HBV infection, pegylated interferon-α (pegIFNα) and
nucleos (t) ide analog (NA), can suppress HBV replication, reverse liver inflammation and …

Background and aims The efficacy of achieving HBsAg clearance through pegylated
interferon (PEG-IFNα) therapy in patients with chronic hepatitis B (CHB) remains uncertain …

New hepatitis B virus (HBV) infections are decreasing owing to improved antiviral therapy
and increased HBV vaccination worldwide; however, the number of HBV infections remains …